Health

AstraZeneca Secures 2 FDA Approvals in Bladder Cancer, Myasthenia Gravis

AstraZeneca said Friday it received U.S. FDA approval for its Imfinzi-Padcev combination in muscle-invasive bladder cancer, and on Monday for KLYGEFA in generalized myasthenia gravis. The bladder cancer approval was based on the VOLGA trial showing a 42% lower risk of death, while KLYGEFA is a new treatment for the rare autoimmune disease.

The FDA granted the bladder cancer approval based on the Phase 3 VOLGA trial, which enrolled 695 patients at 182 centers in 25 countries, according to AstraZeneca. The event-free survival hazard ratio corresponded to a 49% lower risk of disease progression, recurrence, not undergoing surgery, or death, the company said.

Results presented at the European Society for Medical Oncology congress in October and published in the New England Journal of Medicine showed the combination reduced the risk of death by 42% compared with surgery-based care.

The approval covers adults with muscle-invasive bladder cancer who are ineligible for, or decline, cisplatin-based chemotherapy. AstraZeneca said as many as half of patients with muscle-invasive bladder cancer cannot receive cisplatin because of impaired kidney function or other health conditions. The FDA granted the application Priority Review before approval.

Under the approved regimen, patients receive three 21-day cycles of Imfinzi 1,500 mg every three weeks plus Padcev 1.25 mg/kg on days 1 and 8 of each cycle before radical cystectomy, according to the company. After surgery, patients continue Imfinzi alone every four weeks for up to nine cycles.

Grade 3 or 4 adverse events of any cause occurred in 64% of patients on the Imfinzi combination versus 44% in the comparator arm, according to AstraZeneca. The journal publication reports grade 3 or higher rates of 71.1% on the doublet versus 50.2% in controls; the two sets of figures are not directly comparable. Padcev carries a boxed warning for severe skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, which occur predominantly during the first cycle of treatment, according to the label. Padcev’s warnings also include hyperglycemia, pneumonitis, peripheral neuropathy and ocular disorders. Imfinzi’s label carries warnings for severe and fatal immune-mediated reactions.

The approval is AstraZeneca’s third bladder cancer indication in about two years, following the NIAGARA regimen approved in March 2025 and the May 2026 approval of Imfinzi plus BCG for BCG-naive, high-risk non-muscle-invasive disease based on the POTOMAC trial. Merck’s Keytruda plus Padcev was approved before and after surgery for cisplatin-ineligible muscle-invasive bladder cancer on Nov. 21, 2025, and in July 2026 the FDA widened that label to all muscle-invasive bladder cancer patients regardless of cisplatin eligibility. The Imfinzi label remains within the cisplatin-ineligible group. No head-to-head trial compares the two regimens, and the trials differ in design, comparator handling and follow-up, so differences in hazard ratios should not be read as a ranking. The clearest difference is schedule: the Keytruda regimens continue Padcev after surgery, while the Imfinzi regimen stops Padcev at surgery.

Astellas and Pfizer co-developed Padcev. Astellas reported Padcev sales of approximately ¥221.2 billion, about $1.4 billion, in the fiscal year ended March 2026, up 35%.

For myasthenia gravis, the FDA approved KLYGEFA (gefurulimab-gaks), a dual-binding nanobody C5 inhibitor developed by Alexion, AstraZeneca Rare Disease, for generalized myasthenia gravis. The approval was based on the Phase 3 PREVAIL trial, which demonstrated improvement from baseline in the Myasthenia Gravis Activities of Daily Living score at week 26 compared with placebo, according to the Muscular Dystrophy Association. A clinically meaningful improvement was observed as early as week one and sustained through week 26. The therapy is administered with a once-weekly subcutaneous, self-administered autoinjector.

Generalized myasthenia gravis is a chronic autoimmune disorder characterized by muscle weakness that can affect breathing, mobility and communication. The condition affects approximately 37 people per 100,000 in the United States and can occur at any age, according to the MDA.

“Today’s approval represents meaningful progress for people living with generalized myasthenia gravis,” Angela Lek, PhD, chief research officer of the Muscular Dystrophy Association, said in a statement. The MDA has invested more than $1.2 billion in research, including more than $57 million in MG research, since its inception.

Alexion will host an industry update webinar on Tuesday, Dec. 8, to discuss KLYGEFA, according to the MDA.

The World Health Organization has issued two medical product alerts on falsified Imfinzi 500 mg/10 mL vials found in unregulated supply chains, in December 2024 and May 2025. According to the alerts, some vials contained no active ingredient.

.

Evan Vega

Evan Vega is a national affairs correspondent covering politics, public health, and regional policy across multiple states. His reporting connects statehouse developments to their real-world impact on communities. Evan has covered three presidential cycles and specializes in the intersection of state governance and federal policy.